Primary Biliary Cholangitis (PBC): Diagnosis, Treatment & Long‑Term Management
What Is Primary Biliary Cholangitis?
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that slowly destroys the small bile ducts inside the liver. As these ducts disappear, bile backs up (cholestasis), triggering inflammation, scarring (fibrosis), and eventually cirrhosis. The condition strikes women far more often than men—about a 9:1 ratio—and typically appears between ages 40 and 60.
How PBC Presents
Early Stage (Often Silent)
- Fatigue – affects roughly 80% of patients.
- Pruritus (itching) – 55–70%; often worse at night.
- Sicca symptoms – dry eyes and mouth.
Late Stage
- Jaundice, enlarged liver/spleen, ascites, variceal bleeding.
- Osteoporosis and bone fractures.
- High cholesterol (especially HDL) and xanthelasmas (cholesterol deposits around eyelids).
Common Autoimmune Companions
Sjögren’s syndrome, autoimmune thyroiditis, CREST syndrome, Raynaud’s phenomenon, and celiac disease frequently co-exist.
Making the Diagnosis (Any 2 of 3)
- Biochemistry: Alkaline phosphatase (ALP) >1.5× the upper limit of normal for at least 6 months.
- Serology: Anti‑mitochondrial antibody (AMA) ≥1:40 (95% specific) or PBC‑specific ANAs (anti‑sp100, anti‑gp210).
- Histology: Florid duct lesion with granulomatous destruction of interlobular ducts (mainly used when AMA is negative).
Staging the Disease
Histologic Stages (Ludwig/Scheuer)
- Stage 1 – Portal inflammation and duct injury.
- Stage 2 – Periportal fibrosis.
- Stage 3 – Bridging fibrosis.
- Stage 4 – Cirrhosis.
Non‑Invasive Fibrosis Assessment
Transient elastography (FibroScan), Enhanced Liver Fibrosis (ELF) test, and magnetic resonance elastography (MRE) can track fibrosis without biopsy.
Treatment Strategies
First‑Line: Ursodeoxycholic Acid (UDCA)
- Dose: 13–15 mg/kg/day, divided.
- Response criteria at 12 months (Paris‑2, Toronto, Barcelona): ALP <3× ULN, AST <2× ULN, bilirubin ≤1 mg/dL.
- Biochemical responders enjoy near‑normal life expectancy.
Second‑Line (Incomplete Responders or UDCA‑Intolerant)
- Obeticholic Acid (OCA): FXR agonist, 5–10 mg/day. Monitor for pruritus, LDL rise, and gallstones.
- Fibrates (bezafibrate, fenofibrate): Off‑label PPAR‑α agonists that lower ALP and often improve itch. Watch renal function and myopathy risk with concurrent statins.
- Budesonide: Considered in early, non‑cirrhotic disease; evidence remains limited.
Symptom Management
- Pruritus: Cholestyramine (dose separated from UDCA), rifampicin 150 mg/day, naltrexone, sertraline. OCA may worsen itch.
- Fatigue: Modafinil (off‑label); screen/treat depression and sleep apnea.
- Sicca: Artificial tears, saliva substitutes, pilocarpine.
- Osteoporosis: DEXA every 2–3 years; bisphosphonates if T‑score ≤−2.5 or prior fracture.
- Hyperlipidemia: Usually atheroprotective (high HDL); statins only if ASCVD indication exists.
Long‑Term Surveillance
- Labs every 3–6 months: ALP, bilirubin, albumin, INR, platelets.
- HCC surveillance (ultrasound ± AFP every 6 months) once cirrhosis is diagnosed.
- Variceal screening (EGD) at cirrhosis diagnosis, then every 1–3 years.
- Fat‑soluble vitamins (A, D, E, K) if cholestasis is significant.
Liver Transplantation
Indicated for decompensated cirrhosis, intractable pruritus, or hepatocellular carcinoma. Five‑year survival exceeds 85%. Disease recurs in ~20–30% of recipients at 10 years.
Pediatrics - Related Articles
- Understanding Clinical Child Psychology: Diagnosis & Treatment
- Travel Nursing for Pediatric Nurses: Requirements & Opportunities
- Medical Record Retention for Minors: Legal Requirements and Best Practices
- Pediatric Age Ranges: Standard Definitions
- Anesthesia for Children: Understanding Risks & Benefits
- Strep Throat Transmission: Streptococcus Pyogenes Spreads via Respiratory Droplets
- Understanding Mood Stabilizers for Children: Bipolar Disorder & Mania
